David W. Lim MD PhD

Really proud of all the research students who joined my lab @wchospital.bsky.social this summer and presented their work this week at university of Toronto IMS SURP Research day and @wchospital.bsky.social summer student research symposium day! all the best for the future!

Really nice to see #lobular #breastcancer get its own session at the recent Canadian Breast Cancer Symposium #CBCS25, with @lobularbca.bsky.social board members in attendance!

An honour to receive a @bcrfcure.bsky.social Career Development Award at the @conquercancer.bsky.social grants & awards ceremony at the annual @ascocancer.bsky.social meeting.

Grateful for funding to support my breast cancer research program at @wchospital.bsky.social and @uoftsurgery.bsky.social

Congratulations to our @uoftsurgery.bsky.social Breast surgical oncology fellow Dr. Richa Jaiswal on receiving a 2025 @conquercancer.bsky.social Merit Award for her abstract at the upcoming @ascocancer.bsky.social annual meeting! 👏🏻
#ASCO25

We are looking for a Permanent Full-Time Research Assistant II to join my growing research team at Women’s College Hospital !🇨🇦

If you have prior research experience and an interest in breast cancer research, women’s health and/or health equity, please apply! 👇🏻

jobs.dayforcehcm.com/en-US/wch/CA...

Enjoyed speaking on #lobular #breastcancer at the 2025 updates in #generalsurgery conference. @uoftsurgery.bsky.social

Looking forward to speaking about #TNBC at the lunchtime symposium .

A big welcome to Dr Sarah McLaughlin @mayocliniccancer.bsky.social speaking on management of the axilla after neoadjuvant therapy in #breastcancer at the update in #generalsurgery course #bcsm #ugs2025 @uoftsurgery.bsky.social

Dr Sean Cleary kicking off the 2025 update in #generalsurgery course, looking forward to a morning of #breast updates! #UGS2025 @uoftsurgery.bsky.social

Selective Elimination of Breast Surgery for Invasive Breast Cancer This nonrandomized trial examines 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients with breast cancer selected with image-guided vacuum assisted biopsy.

Presented today at #SSO25
After 5 years in well-selected exceptional responders with triple negative and HER2+ breast cancers, there was no ipsilateral tumour recurrence! @socsurgonc.bsky.social
#SSO2025

jamanetwork.com/journals/jam...

Really enjoyed visiting @ubcmedicine.bsky.social and beautiful #Vancouver as a keynote speaker at their 2025 #breast symposium and speaking with colleagues and general surgery residents!

An amazing #breastcancer team at @providencehealthbc.bsky.social! Thanks for the invitation!

Thanks for the invitation @oncologyeducation.bsky.social! It was a pleasure debating Dr. Simmons and seeing everyone!

Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models - Breast Cancer Research Background Epidemiological studies associate an increase in breast cancer risk, particularly triple-negative breast cancer (TNBC), with lack of breastfeeding. This is more prevalent in African America...

What do we know about how the biology of mammary gland lactation and involution impact breast cancer risk?

Building on work from Dr. Pepper Schedin & many others, new work in #BreastCancerResearch from Ramaswamy Lab @osucccjames.bsky.social

link.springer.com/article/10.1...

Dr. Singh draws nice comparisons between SOUND and INSEMA. #SABCS24 @oncoalert.bsky.social @sabcs.bsky.social

Micromets after neoadjuvant portend a worse prognosis and we need to develop a subtype-specific approach.
#SABCS24 @oncoalert.bsky.social

Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study | Journal of Clinical Oncology PURPOSEThe nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is no...

Doing less is sometimes more #supponc #survonc #FirstDoNoHarm #bcsm

ascopubs.org/doi/10.1200/...

Vaginal Estrogen Therapy Use and Survival in Breast Cancer This cohort study compares the mortality risk associated with vaginal estrogen therapy vs no hormone replacement therapy in 2 cohorts of patients with breast cancer in Scotland and Wales.

Study in #JAMAOnc from Scotland/Wales of nearly 50k #breastcancer patients suggests vaginal estrogen use *NOT* associated w increase risk of breast cancer-specific mortality.

More reassuring data 👍

jamanetwork.com/journals/jam...

Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach | JCO Oncology Practice Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MB...

Recommend this excellent review from @BCJoyceO and co
“Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach” #MedTwitter #bcsm ascopubs.org/doi/abs/10.1...

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer This cross-sectional study evaluates the prevalence and clinicopathological associations of germline pathogenic or likely pathogenic variants in 2 groups of breast cancer susceptibility genes among a ...

🧵#Oncology #bcsm #MedSky

NEW Study of genetic testing in 729 ppl w/ any stg new #breastcancer:

👉7.3% had def/likely pathogenic mutation
👉5.3% were BRCA 1/2 or PALB2 (1/3 PARPi-eligible)

Highest odds: fam w/ ovarian ca (9.8x), age <40 (6.8x), TNBC (3.2x).

jamanetwork.com/journals/jam...